Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
A key reimbursement policy panel on September 30 backed plans to expand price cuts under Japan’s cost-effectiveness assessment (CEA) system by the end of 2026, rebuffing the pharmaceutical industry’s call for a freeze on CEA-based price adjustments. Under the expanded…
To read the full story
Related Article
- CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
September 30, 2026
- More Company Involvement in CEA a Big Positive: C2H Researcher
September 29, 2026
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
- CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
REGULATORY
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
- MHLW Panel Backs Easing Protopic Contraindication for Young Children
September 30, 2026
- PMDA Flags New Safety Risks with 3 Drugs
September 30, 2026
- CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…